** Shares in Laboratorios Rovi ROVI.MC fall 16%, set for their worst day in nearly 15 years, after the Spanish pharmaceutical company said it expected its 2024 EBITDA to come lower than market consensus
** It forecasts its 2024 EBITDA to be between 10% and 15% lower than 2024 EBITDA levels expected by market consensus, due to anticipated lower activity in its contract manufacturing $(CDMO)$ business in Q4
** Rovi also said it maintains its guidance for 2025
** "We expect a negative reaction because the impact on EBITDA is relevant and because it will once again raise doubts about its CDMO business, which today is the most relevant," says Sabadell broker in a note
** The lower demand of Covid-19 vaccines from Moderna MRNA.O, that Rovi manufactures, would be the main reason for the lower activity in Q4, says a Renta 4 analyst
** The company is due to report its full year results on February 25
** Shares at their lowest level since December 2023
(Reporting by Joao Manuel Mauricio)
((JoaoManuel.VicenteMauricio@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。